Abstract |
KRAS mutations hinder therapeutic efficacy of epidermal growth factor receptor (EGFR)-specific monoclonal antibodies cetuximab and panitumumab-based immunotherapy of EGFR+ cancers. Although cetuximab inhibits KRAS-mutated cancer cell growth in vitro by natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), KRAS-mutated colorectal carcinoma (CRC) cells escape NK cell immunosurveillance in vivo. To overcome this limitation, we used cetuximab and panitumumab to redirect Fcγ chimeric receptor (CR) T cells against KRAS-mutated HCT116 colorectal cancer (CRC) cells. We compared four polymorphic Fcγ-CR constructs including CD16158F -CR, CD16158V -CR, CD32131H -CR, and CD32131R -CR transduced into T cells by retroviral vectors. Percentages of transduced T cells expressing CD32131H -CR (83.5 ± 9.5) and CD32131R -CR (77.7 ± 13.2) were significantly higher than those expressing with CD16158F -CR (30.3 ± 10.2) and CD16158V -CR (51.7 ± 13.7) (p < 0.003). CD32131R -CR T cells specifically bound soluble cetuximab and panitumumab. However, only CD16158V -CR T cells released high levels of interferon gamma (IFNγ = 1,145.5 pg/ml ±16.5 pg/ml, p < 0.001) and tumor necrosis factor alpha (TNFα = 614 pg/ml ± 21 pg/ml, p < 0.001) upon incubation with cetuximab-opsonized HCT116 cells. Moreover, only CD16158V -CR T cells combined with cetuximab killed HCT116 cells and A549 KRAS-mutated cells in vitro. CD16158V -CR T cells also effectively controlled subcutaneous growth of HCT116 cells in CB17-SCID mice in vivo. Thus, CD16158V -CR T cells combined with cetuximab represent useful reagents to develop innovative EGFR+KRAS-mutated CRC immunotherapies.
|
Authors | Roberto Arriga, Sara Caratelli, Giulia Lanzilli, Alessio Ottaviani, Carlo Cenciarelli, Tommaso Sconocchia, Giulio C Spagnoli, Giandomenica Iezzi, Mario Roselli, Davide Lauro, Andrea Coppola, Gianpietro Dotti, Soldano Ferrone, Giuseppe Sconocchia |
Journal | International journal of cancer
(Int J Cancer)
Vol. 146
Issue 9
Pg. 2531-2538
(05 01 2020)
ISSN: 1097-0215 [Electronic] United States |
PMID | 31396956
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2019 UICC. |
Chemical References |
- Antineoplastic Agents, Immunological
- KRAS protein, human
- Receptors, Antigen, T-Cell
- Receptors, IgG
- Proto-Oncogene Proteins p21(ras)
- Valine
- Cetuximab
|
Topics |
- Animals
- Antineoplastic Agents, Immunological
(pharmacology)
- Apoptosis
- Cell Proliferation
- Cetuximab
(pharmacology)
- Colorectal Neoplasms
(genetics, immunology, pathology, therapy)
- Drug Resistance, Neoplasm
- Humans
- Immunotherapy, Adoptive
(methods)
- Male
- Mice
- Mice, SCID
- Mutation
- Proto-Oncogene Proteins p21(ras)
(genetics)
- Receptors, Antigen, T-Cell
(immunology)
- Receptors, IgG
(genetics, immunology)
- Tumor Cells, Cultured
- Valine
(genetics)
- Xenograft Model Antitumor Assays
|